We protect your health through science
Investigation
Immune Pathogenesis and Viral Reservoir
Research Lines
Content with Investigacion .
Nuevos antifúngicos y aspergilosis crónicas.
Epidemiología, resistencia y actividad de nuevos antifúngicos
El conocimiento de la epidemiología y la tasa de resistencia a los antifúngicos es esencial para un manejo adecuado de los pacientes y una estrategia de detección y diagnostico apropiada. La resistencia a los antimicrobianos es hoy una de las mayores amenazas para la salud mundial siendo el desarrollo y comercialización de nuevos compuestos una de las prioridades del sector de la salud. Se han realizado en colaboración con centros del Sistema Nacional de Salud varios estudios poblacionales, con el fin de conocer la epidemiología de los hongos filamentosos en España y la tasa de resistencia a los antifúngicos. Se ha encontrado que más de un 10% de las infecciones por hongos filamentosos están producidas por especies crípticas que suelen ser más resistentes a los antifúngicos. En los últimos años han aparecido varios compuestos con capacidad antifúngica que están en diferentes fases de desarrollo, en nuestro grupo se ensayan estos nuevos compuestos frente a los principales géneros de especies patógenas, incluyendo las especies crípticas multiresistentes.
Aspergilosis Pulmonar Crónica y Aspergilosis Broncopulmonar alérgica
Estas enfermedades ocurren generalmente en personas inmunocompetentes. La incidencia de estas enfermedades es prácticamente desconocida. La ausencia de un diagnóstico apropiado y del tratamiento óptimo complica el manejo de estos pacientes. Varios estudios han documentado la presencia de cepas multiresistentes en estos pacientes, debido a tratamiento prolongados. En esta línea se está trabajando en mejorar el algoritmo diagnóstico de estas enfermedades, así como analizar la epidemiología de las especies aisladas en estas infecciones y la influencia de cambios en el micobioma pulmonar y ambiental.
Enfermedades fúngicas y Salud global
Muchos países de renta media y baja se encuentran en zonas de alta incidencia de hongos, sin embargo, tienen menos herramientas y capacidad diagnóstica para manejarlas. Con el fin de conocer la incidencia de las infecciones oportunistas por hongos y disminuir la muerte asociada a las mismas en pacientes que viven con VIH en Guatemala y en colaboración con el Fondo de acción Global para las infecciones fúngicas (GAFFI), se ha desarrollado una red de unidades de atención integral al sida e implementado un laboratorio central de diagnóstico, que hace de referencia para el diagnóstico en varias infecciones oportunistas. Se ha hecho un estudio de cohortes incluyendo a más de 2500 pacientes HIV+ con un seguimiento de un año. Se han tamizado las principales infecciones fúngicas en este grupo de pacientes permitiendo el acceso al diagnóstico y al tratamiento de las mismas en la mayor parte del país y consiguiendo una disminución de mortalidad en un año del 7%.
Research projects
Content with Investigacion .
1. Relación ambiente-micobioma en pacientes con asma grave. Implicación en el desarrollo de enfermedad y estudio de posibles medidas de prevención hacia la medicina personalizada. Fondo de Investigaciones Sanitarias. IP: Ana Alastruey-Izquierdo. Fechas: 2021-2023
2. MixInYest: a multicenter survey on mixed yeast infections in Europe. ESCMID IP: Ana Alastruey-Izquierdo. Fechas: 2018-2021
3. Micobioma de muestras respiratorias: desarrollo de base de datos de comparación, estandarización, caracterización y estudio de su influencia en la evolución de enfermedad. Fondo de Investigaciones Sanitarias IP: Ana Alastruey-Izquierdo. Fechas: 2017-2021
4. Minimising HIV deaths through rapid fungal diagnosis and better care in Guatemala. Funding Global Action Fund for Fungal Infections and JYLAG. IP: Ana Alastruey-Izquierdo and Juan Luis Rodríguez-Tudela. Fechas: 2015-2020
5. CPAepi: CPAepi: Epidemiology of Aspergillus strains isolated from patients suffering of CPA. European Confederation of Medical Mycology (ECMM). IP: Ana Alastruey-Izquierdo. Fechas: 2019-2020
6. In vitro activity of SCY-078 and comparators against clinical isolates of Aspergillus spp. Scynexis. IP: Ana Alastruey-Izquierdo. Fechas: 2018-2019
7. In vitro activity of F901318 and comparators against clinical isolates of clinical isolates of Scedosporium and Lomentospora. F2G LTD. IP: Ana Alastruey-Izquierdo. Fechas: 2017-2018
8. In vitro activity of F901318 and comparators against clinical isolates of clinical isolates of cryptic species of Aspergillus. Funding: F2G LTD. IP: Ana Alastruey-Izquierdo. Fechas: 2016-2017
9. In vitro activity of APX001A and comparators against clinical isolates of clinical isolates of rare moulds. Ana Alastruey-Izquierdo. Fechas: 2016-2017
10. Population-Based Prospective Surveillance on Triazole Resistance in Aspergillus and other moulds in Spain (FILPOP_2 study). GILEAD Sciences. Ana Alastruey-Izquierdo and Manuel Cuenca Estrella. Fechas: 2015-2017
11. Estudio epidemiológico de las resistencias a los antifúngicos mediante secuenciación genómica y análisis bioinformático para el diseño de técnicas diagnosticas útiles en laboratorios clínicos (2014-2017). Fondo de Investigaciones Sanitarias Ana Alastruey-Izquierdo. Fechas: 2014-2017
Publications
Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.
3. Lameijer M, Binderup T, van Leent M, Senders M, Fay F. Seijkens T, Kroon J, Stroes E, Kjaer A, Ochando J, Reiner T, Pérez-Medina C, Calcagno C, Fischer E, Zhang B, Temel R, Swirski F, Nahrendorf M, Fayad Z, Lutgens E, Mulder W and Duivenvoorden R. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering. 2018. 2: 279–292.
PUBMED DOINeutrophil derived CSF1 induces macrophage polarization and promotes transplantation tolerance.
4. Braza MS, Conde P, Garcia MR, Cortegano I, Brahmachary M, Pothula V, Fay F, Boros P, Werner SW, Ginhoux F, Mulder WJ, and Ochando J. Neutrophil derived CSF1 induces macrophage polarization and promotes transplantation tolerance. Am J Transplant. 2018.
PUBMED DOIDC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance
9. Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang J, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, Bronte V, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. 2015. DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. Immunity. 16;42(6):1143-58.
PUBMED DOIProteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis
2.- Proteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis. Antonio Infantes-Lorenzo, Jose; Moreno, Inmaculada; Angeles Risalde, Maria; et ál. CLINICAL PROTEOMICS Volumen: 14 Número de artículo: 36 Fecha de publicación: NOV 2 2017
PUBMED DOIFunctional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
3.- Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. Subias Hidalgo, Marta; Yebenes, Hugo; Rodriguez-Gallego, Cesar; et ál..EUROPEAN JOURNAL OF IMMUNOLOGY Volumen: 47 Número: 3 Páginas: 504-515 Fecha de publicación: MAR 2017
PUBMED DOIImmunoproteomic characterisation of Mycoplasma mycoides subspecies capri by mass spectrometry analysis of two- dimensional electrophoresis spots and western blot
5.- Immunoproteomic characterisation of Mycoplasma mycoides subspecies capri by mass spectrometry analysis of two- dimensional electrophoresis spots and western blot. Churchward, Colin P.; Rosales, Ruben S.; Gielbert, Adriana; et ál..JOURNAL OF PHARMACY AND PHARMACOLOGY Volumen: 67 Número: 3 Número especial: SI Páginas: 364-371 Fecha de publicación: MAR 2015
PUBMED DOIEfficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
6.- Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis. Corral, M. Jesus; Serrano, Dolores R.; Moreno, Inmaculada; et ál..JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY Volumen: 69 Número: 12 Páginas: 3268-3274 Fecha de publicación: DEC 2014
PUBMED DOIA Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models
7.- A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Subias, Marta; Tortajada, Agustin; Gastoldi, Sara; et ál..JOURNAL OF IMMUNOLOGY Volumen: 193 Número: 11 Páginas: 5567-5575 Fecha de publicación: DEC 2014
PUBMED DOIDetection of anti-Leishmania infantum antibodies in sylvatic lagomorphs from an epidemic area of Madrid using the indirect immunofluorescence antibody test
8.- Detection of anti-Leishmania infantum antibodies in sylvatic lagomorphs from an epidemic area of Madrid using the indirect immunofluorescence antibody test. Moreno, Inmaculada; Alvarez, Julio; Garcia, Nerea; et ál..VETERINARY PARASITOLOGY Volumen: 199 Número: 3-4 Páginas: 264-267 Fecha de publicación: 2014
PUBMED DOIEvidence of Leishmania infantum Infection in Rabbits (Oryctolagus cuniculus) in a Natural Area in Madrid, Spain.
9.- Evidence of Leishmania infantum Infection in Rabbits (Oryctolagus cuniculus) in a Natural Area in Madrid, Spain. Garcia, Nerea; Moreno, Inmaculada; Alvarez, Julio; et ál..BIOMED RESEARCH INTERNATIONAL Número de artículo: 318254 Fecha de publicación: 2014
PUBMED DOIMucus-Activatable Shiga Toxin Genotype stx2d in Escherichia coli O157:H7
2. Sánchez, S., Llorente, M.T., Herrera-León, L., Ramiro, R., Nebreda, S., Remacha, M.A., Herrera-León, S. Mucus-activatable shiga toxin genotype stx2d in Escherichia coli O157:H7. (2017) Emerging Infectious Diseases, 23 (8), pp. 1431-1433.
PUBMED DOIMultinational outbreak of travel-related Salmonella Chester infections in europe, summers 2014 and 2015
3. Fonteneau, L., Da Silva, N.J., Fabre, L., Ashton, P., Torpdahl, M., Müller, L., Bouchrif, B., El Boulani, A., Valkanou, E., Mattheus, W., Friesema, I., Herrera Leon, S., Varela Martínez, C., Mossong, J., Severi, E., Grant, K., Weill, F., Gossner, C.M., Bertrand, S., Dallman, T., Le Hello, S. Multinational outbreak of travel-related Salmonella Chester infections in europe, summers 2014 and 2015. (2017) Eurosurveillance, 22 (7).
PUBMED DOIProspective use of whole genome sequencing (WGS) detected a multi-country outbreak of Salmonella Enteritidis
4. Inns, T., Ashton, P.M., Herrera-Leon, S., Lighthill, J., Foulkes, S., Jombart, T., Rehman, Y., Fox, A., Dallman, T., De Pinna, E., Browning, L., Coia, J.E., Edeghere, O., Vivancos, R. Prospective use of whole genome sequencing (WGS) detected a multi-country outbreak of Salmonella Enteritidis (2017) Epidemiology and Infection, 145 (2), pp. 289-298.
PUBMED DOIPlasmid-mediated quinolone resistance in different diarrheagenic Escherichia coli pathotypes responsible for complicated, noncomplicated, and traveler's diarrhea cases.
5. Herrera-Leon, S., Llorente, M.T., Sanchez, S. Plasmid-mediated quinolone resistance in different diarrheagenic Escherichia coli pathotypes responsible for complicated, noncomplicated, and traveler's diarrhea cases. (2016) Antimicrobial Agents and Chemotherapy, 60 (3), pp. 1950-1951.
PUBMED DOIMolecular Epidemiology and Antibiotic Susceptibility of Vibrio cholerae Associated with a Large Cholera Outbreak in Ghana in 2014.
6. Eibach, D., Herrera-León, S., Gil, H., Hogan, B., Ehlkes, L., Adjabeng, M., Kreuels, B., Nagel, M., Opare, D., Fobil, J.N., May, J. Molecular Epidemiology and Antibiotic Susceptibility of Vibrio cholerae Associated with a Large Cholera Outbreak in Ghana in 2014. (2016) PLoS Neglected Tropical Diseases, 10 (5).
PUBMED DOIWhat’s in a name? Species-wide whole-genome sequencing resolves invasive and noninvasive lineages of Salmonella enterica serotype Paratyphi B
7. Connor, T.R., Owen, S.V., Langridge, G., Connell, S., Nair, S., Reuter, S., Dallman, T.J., Corander, J., Tabing, K.C., Le Hello, S., Fookes, M., Doublet, B., Zhou, Z., Feltwell, T., Ellington, M.J., Herrera, S., Gilmour, M., Cloeckaert, A., Achtman, M., Parkhill, J., Wain, J., De Pinna, E., Weill, F.-X., Peters, T., Thomson, N. What’s in a name? Species-wide whole-genome sequencing resolves invasive and noninvasive lineages of Salmonella enterica serotype Paratyphi B (2016) mBio, 7 (4).
PUBMED DOIInvasive salmonella infections among children from Rural Mozambique, 2001-2014
9. Mandomando, I., Bassat, Q., Sigaúque, B., Massora, S., Quintó, L., Ácacio, S., Nhampossa, T., Vubil, D., Garrine, M., Macete, E., Aide, P., Sacoor, C., Herrera-León, S., Ruiz, J., Tennant, S.M., Menéndez, C., Alonso, P.L. Invasive salmonella infections among children from Rural Mozambique, 2001-2014 (2015) Clinical Infectious Diseases, 61, pp. S339-S345.
PUBMED DOIContent with Investigacion .
-
Ana Alastruey Izquierdo
Research Scientist
ORCID code: 0000-0001-8651-4405
Doctor in microbiology from the Complutense University of Madrid and Master in Bioinformatics and computational biology from the same university. He completed his doctoral thesis at the ISCIII under the supervision of Dr. Juan Luis Rodríguez Tudela in molecular identification of human pathogenic fungi. He carried out research stays in Holland (Fungal Biodiversity Center, CBS-Knaw, Utrecht) and Austria (Austrian Institute of Technology). In 2010-2011 he joined Dr. David Perlin's group as a postdoctoral fellow at the Public Health Research Institute of Rutgers University in the United States working on antifungal resistance. In 2012 and 2013 he carried out research stays at the European Bioinformatics Institute (EMBL-EBI). Since 2014 he has been a Senior Scientist at the ISCIII.
-
Laura Alguacil Cuéllar
PhD student (pFIS)
ORCID code: 0000-0002-7362-0214
Graduated in Biology from the Rey Juan Carlos University, she completed the Master's Degree in Microbiology and Parasitology: Research and Development from the Complutense University of Madrid (UCM) and is an expert in Research Methodology and Evidence-Based Clinical Practice from the Miguel de Cervantes European University. For two years he was a research assistant in the Microbiology department of the Faculty of Pharmacy at the UCM thanks to a CM Young Employment Scholarship. In 2023 he joined ISCIII with a pFIS predoctoral contract under the direction of Dr. Ana Alastruey Izquierdo.
List of staff
Additional Information
Contact Information
María Teresa Coiras
918223782
mcoiras@isciii.es
generic email: pirv.isciii@gmail.com
Scientific Societies
• Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
• AIDS Study Group (GeSIDA) of SEIMC.
• PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).
Other links
You can follow the activity of our group in Twitter (X), Instagram and Linkedin.
Collaboration in other projects
Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections. Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545
Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024
Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924
Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025
Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006
Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22
Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006
Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877
Contact Information
María Teresa Coiras
918223782
mcoiras@isciii.es
generic email: pirv.isciii@gmail.com
Scientific Societies
• Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
• AIDS Study Group (GeSIDA) of SEIMC.
• PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).
Other links
You can follow the activity of our group in Twitter (X), Instagram and Linkedin.
Collaboration in other projects
Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections. Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545
Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024
Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924
Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025
Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006
Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22
Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006
Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877